Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FHUHJ
ADC Name
ScFvGPIIb/IIIa-MMAE
Synonyms
ScFvGPIIb/IIIa MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 4 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
Myxofibrosarcoma [ICD11:2B53]
Investigative
Prostate cancer [ICD11:2C82]
Investigative
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
2
Antibody Name
Anti-ITGA2B scFv
  Antibody Info 
Antigen Name
Integrin beta-3 (ITGB3)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Site-specific conjugation through the Sortase A at the C-terminal of heavy and light chain.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.2
nM
MDA-MB-231 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.20 nM High ITGA2B expression (ITGA2B+++/++)
Method Description
The MTT-based cytotoxicity assay in MDA-MB-231 cells that displayed a dose dependent cell killing of ADC treatment.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics. 2019 Feb 7;9(4):1154-1169. doi: 10.7150/thno.29146. eCollection 2019.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.